ERBB2 and neoplasm: In addition, pertuzumab (P), a second mAb that binds to a different epitope of HER2 than H, was shown to provide a complementary mechanism for disrupting HER2 signaling, resulting in enhanced anti-tumor activity (Eiger et al. 2019).